Total: $11.5M

Year to Date: $296.83M


Company (Location)

Partner (Location)

Amt. (M)

Details (Date)


Adamis Pharmaceuticals Corp. (San Diego)

Eses Holdings Ltd.

$2.5

For achieving a set of milestones in its prostate cancer program (7/27)

Regulus Therapeutics Inc. (La Jolla, Calif.)

GlaxoSmithKline plc (London)

ND

For the identification of a third microRNA target in their alliance (7/21)

Rib-X Pharmaceuticals Inc. (New Haven, Conn.)

Sanofi SA (Paris)

$9

For the recent signing of a potential $760M collaboration and option agreement for antibiotics resulting from Rib-X's RX-04 program against drug-resistant Gram-negative and Gram-positive pathogens; the payment was triggered by the achievement of research-based milestones (7/20)

Siena Biotech SpA (Siena, Italy)

Roche AG (Basel, Switzerland)

ND

As part of their 2007 neurodegenerative disease collaboration; Roche took the lead last year on developing and commercializing selected molecules to treat Alzheimer's disease (7/20)


Notes:

Currency conversions are based on exchange rates at the time of the deal.

The date indicated refers to the BioWorld Today issue in which the news item can be found.

ND = Not disclosed. ** Denotes the date the item ran in BioWorld International.